Journal of Radiology
ISSN: 2167-7964
Ivan, J Radiol 2025, 14:1
Editorial Open Access

# Use of MRI in the Detection of Adrenal Pheochromocytomas and Paragangliomas in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2)

**Ivan Petrov***

*Department of Radiology, Sapienza University of Rome, Italy*

## Introduction

Multiple Endocrine Neoplasia Type 2 (MEN2) is a rare genetic disorder characterized by the development of tumors in multiple endocrine glands, primarily affecting the thyroid, parathyroids, and adrenal glands. MEN2 is most commonly associated with mutations in the RET proto-oncogene and is subclassified into two main categories: MEN2A and MEN2B. Both forms of MEN2 increase the risk of developing medullary thyroid carcinoma (MTC), pheochromocytomas, and parathyroid adenomas. Among these, adrenal pheochromocytomas and extra-adrenal paragangliomas represent a significant concern due to their potential for malignant transformation, secretory activity, and the resultant clinical consequences. Early detection and accurate localization of these tumors are crucial for managing MEN2 patients and preventing life-threatening complications, such as hypertensive crises associated with pheochromocytomas. Magnetic resonance imaging (MRI) has become an increasingly important tool in the detection and monitoring of these tumors in MEN2 patients. This article discusses the role of MRI in the detection of adrenal pheochromocytomas and paragangliomas in patients with MEN2, highlighting its advantages, limitations, and clinical relevance [1].

## Adrenal Pheochromocytomas and Paragangliomas in MEN2

Pheochromocytomas are rare tumors that originate from chromaffin cells in the adrenal medulla and produce excessive catecholamines, leading to symptoms such as hypertension, tachycardia, headache, sweating, and palpitations. In MEN2, the presence of pheochromocytomas is particularly concerning due to their high potential for malignancy and their association with other endocrine abnormalities, such as MTC. Paragangliomas, which arise from chromaffin cells outside the adrenal glands, share similar clinical features with pheochromocytomas, including the secretion of catecholamines. Both pheochromocytomas and paragangliomas can occur in various locations, including the abdomen, pelvis, neck, and thorax, and are associated with the same genetic mutations seen in MEN2. The early detection of pheochromocytomas and paragangliomas in MEN2 patients is crucial for managing the associated hypertensive episodes and preparing for appropriate surgical interventions. Given the genetic predisposition in MEN2, patients often undergo routine screening for these tumors, with various imaging modalities being employed for detection and monitoring. Among these imaging techniques, MRI has become increasingly favored due to its non-invasive nature, high-resolution imaging, and lack of ionizing radiation, making it particularly useful for long-term monitoring in MEN2 patients [2].

## MRI in the Detection of Adrenal Pheochromocytomas

MRI plays a vital role in the detection of adrenal pheochromocytomas in MEN2 patients, offering several advantages over other imaging modalities. One of the primary benefits of MRI is its ability to provide high-resolution images of the adrenal glands without the need for ionizing radiation, which is particularly advantageous for patients requiring frequent imaging. MRI can detect small pheochromocytomas, even those that may not be visible on other imaging modalities, such as CT scans, especially in the early stages before tumor growth becomes clinically significant. On MRI, pheochromocytomas typically present as well-defined, homogeneously enhancing masses that are isointense or slightly hypointense on T1-weighted images and hyperintense on T2-weighted images. These characteristics make it possible to differentiate pheochromocytomas from other adrenal masses, such as adrenal adenomas or metastatic lesions. In some cases, gadolinium-based contrast agents can be used to enhance the detection of pheochromocytomas, as these tumors generally show significant enhancement after contrast administration due to their highly vascular nature [3]. Diffusion-weighted imaging (DWI), a specialized MRI technique, has also been employed to further characterize pheochromocytomas. DWI can provide additional functional information regarding tissue cellularity, which may aid in differentiating pheochromocytomas from other adrenal tumors, particularly when there is ambiguity in conventional imaging. Additionally, functional MRI techniques, such as dynamic contrast-enhanced MRI, may offer insights into tumor perfusion, which is often elevated in pheochromocytomas due to their rich blood supply [4].

## MRI in the Detection of Paragangliomas

Paragangliomas, which can occur in extra-adrenal locations, are similarly well-visualized with MRI. Paragangliomas often present as heterogeneous masses that can vary in signal intensity depending on their vascularity, cystic components, and degree of hemorrhage. These tumors are typically hyperintense on T2-weighted images, while they may be hypointense or isointense on T1-weighted images, similar to pheochromocytomas. After the administration of gadolinium contrast, paragangliomas usually demonstrate significant enhancement due to their vascularity, making them distinguishable from other types of masses [5]. MRI is particularly useful in identifying paragangliomas located in the neck, thorax, and abdomen, regions that are more challenging to assess with other imaging modalities. For example, in patients with MEN2, paragangliomas in the neck (often referred to as carotid body tumors) can be detected early through MRI, enabling timely intervention before the tumors grow large enough to cause compressive symptoms or become malignant. Functional MRI techniques can also

***Corresponding author:** Ivan Petrov, Department of Radiology, Sapienza University of Rome, Italy, E-mail Id: petr_iva33@edu

**Received:** 01-Jan-2025, Manuscript No. roa-25-159628; **Editor assigned:** 03-Jan-2025, Pre-QC No. roa-25-159628 (PQ); **Reviewed:** 20-Jan-2025, QC No. roa-25-159628; **Revised:** 25-Jan-2025, Manuscript No. roa-25-159628 (R); **Published:** 31-Jan-2025, DOI: 10.4172/2167-7964.1000654

**Citation:** Ivan P (2025) Use of MRI in the Detection of Adrenal Pheochromocytomas and Paragangliomas in Patients with Multiple Endocrine Neoplasia Type 2 (MEN2). OMICS J Radiol 14: 654.

aid in assessing the functional activity of paragangliomas, as these tumors tend to have a higher blood flow than other adjacent tissues.

### Challenges and Limitations of MRI

While MRI is an invaluable tool in the detection of adrenal pheochromocytomas and paragangliomas in MEN2 patients, there are some limitations to consider. One challenge is the difficulty in detecting very small tumors or lesions that are located deep within the adrenal glands or surrounding tissues. Although MRI provides high-resolution images, some smaller pheochromocytomas may still be missed, particularly in patients with obesity or poor image quality due to motion artifacts. Additionally, MRI's sensitivity in detecting metastasis from pheochromocytomas or paragangliomas is lower compared to CT or positron emission tomography (PET), which are often preferred for staging purposes in advanced disease. Another limitation of MRI is the high cost and limited availability of the technology, particularly in regions with less access to advanced medical imaging facilities. This can pose a barrier to widespread use of MRI as a routine screening tool for MEN2 patients, especially in resource-limited settings [6].

### Clinical Relevance and Future Directions

The use of MRI in the detection of adrenal pheochromocytomas and paragangliomas in MEN2 patients is clinically relevant due to its non-invasive nature and ability to provide detailed, high-resolution images of both adrenal and extra-adrenal tumors. By enabling early detection and accurate localization of these tumors, MRI allows for more effective management of MEN2, particularly in preventing hypertensive crises and guiding surgical decisions. Furthermore, MRI plays an essential role in the long-term surveillance of MEN2 patients, helping to monitor the growth of tumors and detect any new lesions that may develop over time. Future advancements in MRI technology, such as improved contrast agents, higher magnetic field strengths, and the integration of functional imaging techniques, hold the potential to further enhance the sensitivity and specificity of MRI in detecting pheochromocytomas and paragangliomas. These advancements may lead to better early diagnosis, more precise characterization of tumors, and improved patient outcomes. Additionally, ongoing research into the molecular characteristics of MEN2-associated tumors could help identify new imaging biomarkers that can be detected through MRI, further improving the management of these patients.

## Conclusion

MRI has become a cornerstone in the detection and monitoring of adrenal pheochromocytomas and paragangliomas in patients with Multiple Endocrine Neoplasia Type 2 (MEN2). The ability to provide high-resolution, non-invasive images without ionizing radiation makes MRI particularly advantageous for both the initial detection and long-term surveillance of these tumors. While there are some limitations, including challenges in detecting very small lesions and a lower sensitivity for detecting metastasis, MRI remains a powerful tool for the comprehensive management of MEN2. With ongoing advancements in MRI technology, its role in the detection of pheochromocytomas and paragangliomas is expected to grow, offering more precise and personalized care for patients with this rare genetic disorder.

### References

1. Combs SE, Adeberg S, Dittmar JO, Welzel T, Rieken S, et al. (2017) Skull base meningiomas: long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). BMC Cancer 17: 254.
2. Sahgal A, Weinberg V, Ma L, Chang E, Chao S, et al. (2013) Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. Int J Radiat Oncol Biol Phys 85: 341-347.
3. Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, et al. (2018) An overview of meningiomas. Future Oncol 14: 2161-2177.
4. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, et al. (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122: 4-23.
5. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashbyet LS, et al. (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129: 35-47.
6. Goldsmith BJ, Wara WM, Wilson CB, Larson DA (1994) Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80: 195-201.